NCT05950529

Brief Summary

The goal of this clinical trial is to compare the control of oral malodor between an investigational lozenge with the enzyme polyphenol oxidase plus green coffee extract or an investigational lozenge with color and flavor along with the enzyme polyphenol oxidase plus green coffee extract in generally healthy subjects. Safety will be evaluated also. Subjects will be randomly assigned to one of four study groups (group code: A, B, C or D):

  • Experimental lozenge with the enzyme Polyphenol oxidase and green coffee extract
  • Experimental lozenge with the enzyme Polyphenol oxidase, green coffee extract and flavor
  • Placebo lozenge control (sorbitol only)
  • No product control Subjects will be asked to allow their assigned lozenge to dissolve in the mouth while placed on the dorsal surface of the tongue. Subjects can suck on the lozenge and press the lozenge against the palate; however, the lozenge should not be moved around in the mouth or placed on the buccal mucosa. Subjects should avoid biting or chewing the lozenge and talking while dissolving the lozenge. After the lozenge has completely dissolved, the subject will be instructed to swallow the remaining solution. Immediately (no later than 5 minutes) after subjects use their assigned lozenge product or no product, subjects will receive organoleptic assessments (OI) by the 4-5 trained judges and VSC readings (OralChroma readings). Organoleptic measurements (OI) will be repeated at 30 minutes, 1, 2, 3, and 4 hours following test product use or no test product use. OralChroma measurements will be performed again after 30 minutes, 1, 2, 3, and 4 hours after test product use or no test product. Subjects will complete a post-product performance questionnaire after the 1-hour OI and OralChroma assessments have been administered. Following the 4-hour OralChroma assessment, each subject will receive a final oral soft and hard tissue exam for safety.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
156

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Feb 2020

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 6, 2020

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 11, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 11, 2020

Completed
3.3 years until next milestone

First Submitted

Initial submission to the registry

July 11, 2023

Completed
7 days until next milestone

First Posted

Study publicly available on registry

July 18, 2023

Completed
Last Updated

July 18, 2023

Status Verified

July 1, 2023

Enrollment Period

1 month

First QC Date

July 11, 2023

Last Update Submit

July 11, 2023

Conditions

Keywords

enzymes, oral malodor

Outcome Measures

Primary Outcomes (1)

  • Total VSC (OralChroma) readings

    The mean total VSC (OralChroma) readings from the Baseline assessment to the immediate (5 minutes) assessment following product use.

    5 minutes

Secondary Outcomes (3)

  • OI scores

    5 minutes, 30 minutes, 1, 2, 3, and 4 hours

  • Total VSC (OralChroma) readings

    30 minutes, 1, 2, 3, and 4 hours

  • Three major components of VSCs in mouth air

    5 minutes, 30 minutes, 1, 2, 3, and 4 hours

Study Arms (4)

Group A

EXPERIMENTAL

Experimental lozenge with the enzyme Polyphenol oxidase plus green coffee extract

Other: Experimental lozenge with the enzyme Polyphenol oxidase and green coffee extract

Group B

EXPERIMENTAL

Experimental lozenge with the enzyme Polyphenol oxidase, green coffee extract and flavor

Other: Experimental lozenge with the enzyme Polyphenol oxidase, green coffee extract and flavor

Group C

PLACEBO COMPARATOR

Placebo lozenge Control (sorbitol only)

Other: Placebo lozenge control (sorbitol only)

Group D

OTHER

No Product Control

Other: No product

Interventions

Subjects will be instructed to allow their assigned lozenge to dissolve in the mouth while placed on the dorsal surface of the tongue. Subjects can suck on the lozenge and press the lozenge against the palate; however, the lozenge should not be moved around in the mouth or placed on the buccal mucosa. Subjects should avoid biting or chewing the lozenge and talking while dissolving the lozenge. After the lozenge has dissolved, the subject will be instructed to swallow the remaining solution.

Group A

Subjects will be instructed to allow their assigned lozenge to dissolve in the mouth while placed on the dorsal surface of the tongue. Subjects can suck on the lozenge and press the lozenge against the palate; however, the lozenge should not be moved around in the mouth or placed on the buccal mucosa. Subjects should avoid biting or chewing the lozenge and talking while dissolving the lozenge. After the lozenge has dissolved, the subject will be instructed to swallow the remaining solution.

Group B

Subjects will be instructed to allow their assigned lozenge to dissolve in the mouth while placed on the dorsal surface of the tongue. Subjects can suck on the lozenge and press the lozenge against the palate; however, the lozenge should not be moved around in the mouth or placed on the buccal mucosa. Subjects should avoid biting or chewing the lozenge and talking while dissolving the lozenge. After the lozenge has dissolved, the subject will be instructed to swallow the remaining solution.

Group C

no product

Group D

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • To be eligible for study participation, subjects must meet the following criteria:
  • Generally healthy males and females ≥ 18 years of age.
  • Able to read, sign and receive a copy of the signed informed consent form.
  • Organoleptic score (Odor Intensity) ≥ 2 (morning breath: at least 6-12 hours following oral hygiene, eating or drinking) at Screening Visit, based on the average ratings of at least 4 Odor Intensity judges.
  • Have an OralChroma reading ≥ 125 ppb hydrogen sulfide H2S gas, vsc (at least 6-12 hours after eating or drinking or oral hygiene).
  • Intra-oral cause of bad breath (non-systemic origin) as determined by health history or exam.
  • Have at least 16 natural teeth.
  • Agree to abstain from eating, drinking, chewing gum, and any oral hygiene at least 6-12 hours prior to evaluation of oral malodor (Screening and Baseline visits).
  • Agree to avoid drinking alcohol beverages and eating spicy foods, garlic and onions, cabbage, spices, cauliflower and radishes (sulfur compounds) 48 hours prior to each study visit.
  • Agree to refrain from tongue brushing/cleaning for the duration of the study.
  • Adequate oral hygiene and no signs of oral neglect.
  • Has not taken any type of probiotic supplement intended for oral health within 14 days of screening visit.

You may not qualify if:

  • Subjects presenting with any of the following will not be included in the study:
  • History of allergy or significant adverse effects following use of oral hygiene products such as toothpastes, mouth rinses, breath mints, lozenges, or chewing gum or their ingredients.
  • History of allergies to ingredients in the test product.
  • History of common food allergies (e.g. peanuts, tree nuts, milk, eggs, shellfish, fish, wheat, soybeans)
  • Self-reported as pregnant or nursing.
  • Self-reported serious medical conditions.
  • Based on history and clinical exam: advanced periodontitis, frank caries, and mucosal diseases.
  • Antibiotic or anti-inflammatory medication within 30 days of screening visit.
  • Dental prophylaxis or use of chemotherapeutic antiplaque/antigingivitis oral care products or tooth bleaching within 7 days of screening visit.
  • Smoker and/or user of smokeless tobacco products.
  • Orthodontic appliances, peri/oral piercings, or removable partial dentures.
  • Significant oral soft tissue pathology based on a visual examination.
  • Acute sinusitis or severe oral-pharyngeal infections.
  • Currently taking medications which can cause oral malodor.
  • Reduced salivary flow due to pathological reasons (e.g. Sjögrens syndrome).
  • +2 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Salus Research

Fort Wayne, Indiana, 46825, United States

Location

Related Publications (1)

  • Santos SL, Holz C, Milleman K, Milleman J, Wenqian G, Mateo LR. Effectiveness of a combination of laccase and green coffee extract on oral malodor: a comparative, randomized, controlled, evaluator-blind, parallel-group trial. J Breath Res. 2024 Nov 25;19(1). doi: 10.1088/1752-7163/ad8e7c.

MeSH Terms

Interventions

Flavoring Agents

Intervention Hierarchy (Ancestors)

Pharmaceutic AidsPharmaceutical PreparationsFood AdditivesFood IngredientsSpecialty Uses of ChemicalsChemical Actions and UsesFoodDiet, Food, and NutritionPhysiological PhenomenaFood and Beverages

Study Officials

  • Jeffrey Milleman, DDS, MPA

    Salus Research

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
Oral Malodor examiners are blinded and the subjects do not know which of the 2 lozenges they are taking
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 11, 2023

First Posted

July 18, 2023

Study Start

February 6, 2020

Primary Completion

March 11, 2020

Study Completion

March 11, 2020

Last Updated

July 18, 2023

Record last verified: 2023-07

Data Sharing

IPD Sharing
Will not share

Individual participant data will be kept confidential at the study center will not be shared externally.

Locations